Familial hypercholesterolaemia (FH) is an autosomal dominant disease that warrants early diagnosis to prevent premature cardiovascular disease (CVD). However, genetic testing to make a definite diagnosis is costly, and careful selection of eligible subjects is important. Unfortunately, accuracy of current diagnostic criteria is poor, especially in young individuals. We therefore developed and validated a model to predict the presence of an FH causing mutation in persons referred by general practitioners.
Introduction
Familial hypercholesterolaemia (FH) is a monogenic disorder of lipid metabolism, and patients are characterized by severely elevated levels of low-density lipoprotein cholesterol (LDL-C). 1 The homozygous form is rare and has an estimated prevalence of 1:400 000. 2 Heterozygous FH (HeFH) is much more common and is estimated to affect 1:300 individuals. 2 If left untreated, HeFH patients are at three to four times higher risk for cardiovascular disease (CVD) compared with the general population. 3 Owing to this markedly increased CVD risk and the high prevalence, HeFH poses a significant threat to both individual and public health. Initiation of statin therapy robustly improves lipid levels and CVD risk, especially when initiated at a young age. 4 -7 Early detection of HeFH is therefore a crucial imperative. A definite diagnosis of HeFH is made upon identification of a molecular defect in one of three different genes [the LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9)] 8 that all lead to elevated LDL-C and premature CVD.
Identification of patients with HeFH by means of genetic cascade screening and subsequent initiation of statins was shown to be costeffective, 9 ,10 and molecular testing is therefore recommended in several guidelines. 11 -14 In clinical practice, however, the selection of patients for genetic testing remains a challenge. Currently, three clinical scoring systems are available (criteria of the Simon Broome registry, 15 MEDPED, 16 and Dutch Lipid Clinic Network 17 ), and these have been shown to result in mutation detection rates of 61 -73%, 53, and 54-70%, respectively, among patients with definitive FH. 18 -20 Unfortunately, these algorithms are crude, especially misclassifying young individuals as being unaffected, while it is eminent that particularly the young benefit most from early detection and initiation of treatment. 9 There are two reasons for this misclassification of the young. First, the presence of tendon xanthomas is an important criterion in the Simon Broom and Dutch Lipid Clinic Network criteria, but it is a rare finding in young individuals and therefore may result in misclassifying young HeFH patients as being unaffected. Moreover, fixed, non-age-adjusted cut-off values for LDL-C are used to classify patients. Since LDL-C increases with age, 21 this non-age-adjusted approach also contributes to misclassification. As a consequence, in young patients, HeFH is underdiagnosed and undertreated at an even greater extent than in the elderly. Another limitation of the algorithms is that they require information on family history of hypercholesterolaemia and premature CVD, which is often absent, 22, 23 thus restricting their applicability in clinical practice. So, there is a clear need for an improved prediction algorithm to select individuals for DNA analysis for FH mutations. We therefore set out to develop and externally validate a prediction model enabling the physician to select those patients who are deemed eligible for DNA analysis.
Methods Development cohort: sources of data
For the development of the prediction model, we used the cohort of participants of the Dutch FH screening programme. This nationwide and government-subsidized cascade screening programme was initiated in January 1994 to identify all FH patients in the Netherlands. The screening cascade starts with the identification of a carrier of an FH mutation ('index patient'), followed by DNA analysis in first-degree relatives. Once an FH mutation is identified in one of the relatives, his or her first-degree relatives are subsequently approached for participation as well. A certified genetic fieldworker visits participants at home and gathers demographic and clinical data as well as information on medication use by means of a standardized questionnaire. Further, a blood sample is drawn for DNA analysis and, since 2004, a fasting lipid profile is also measured.
The Dutch FH registry has gone through an extensive review of electronic records in the first quarter of 2015; subjects who were retested for additional mutations after their participation in the screening programme were carefully evaluated. This has resulted in two adaptations in the overall numbers. First, 244 individuals were proved, upon retesting, to carry an FH mutation, so they were transported from the group of unaffected individuals to the FH group. Also, an additional 786 persons of whom first test results were unknown were proved to carry an FH mutation and were added to the FH group.
Subjects were eligible for inclusion in the development cohort if they were screened for FH mutations from January 1994 until January 2014. Homozygous FH patients were excluded. Index patients were included. We performed a sensitivity analysis in which index patients were excluded (see Supplementary material online). All subjects provided written informed consent. This study complies with the Declaration of Helsinki and was approved by the Medical Ethics Committee of the Academic Medical Centre (AMC) in Amsterdam.
Development cohort: lipid profile and mutation analysis
The lipid profile was measured with the LDX analyser (Cholestech Corporation, Hayward, CA, USA). 24 Low-density lipoprotein cholesterol concentrations were calculated using the Friedewald formula, unless triglycerides were .4.5 mmol/L. 25 In patients using lipid-lowering therapy (LLT) at the time of screening, the untreated LDL-C level was calculated according to a validated equation.
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DNA analysis was performed with DNA that was isolated from 10 mL of freshly collected blood containing EDTA as anticoagulant. The method of mutation analysis has been described previously. 27, 28 Validation cohort: sources of data
The external validation dataset consisted of subjects screened at the Chicoutimi Hospital Lipid Clinic or at ECOGENE-21 Clinical Research Center and agreed to participate in studies on genetic determinants of CAD combining genome-wide scans and candidate gene strategies between January 1993 and January 2014. Patients were eligible for current study if they were tested for the heterozygous presence of an FH mutation. The project was approved by the Chicoutimi Hospital Ethics Committee, in accordance with the Declaration of Helsinki.
Validation cohort: lipid profile and mutation analysis
Lipid and lipoprotein levels were determined in fasting patients not using lipid-lowering medication for at least 2 -4 weeks. The lipid profile was determined by enzymatic methods (Randox Co., Crumlin, UK) using a RA-500 analyser (Bayer Corporation Inc., Tarrytown, NY, USA), as previously described. 29 Low-density lipoprotein cholesterol concentrations were calculated using the Friedewald formula, unless triglycerides were .4.5 mmol/L. 25 In patients using LLT at the time of screening, the untreated LDL-C level was calculated according to a validated equation. 26 Identification of the LDLR mutation within the external validation cohort was performed either by Southern blot (for deletions) 30 or by restriction fragment length polymorphism (for point mutations). 31 
Outcome
The outcome of interest was the presence of a deleterious FH mutation. Carriers of a non-deleterious mutation were classified as unaffected subjects. Mutations were considered non-deleterious once in literature non-functionality was shown, or once functionality tests carried out by the laboratory of Experimental Vascular Medicine in the AMC showed non-functionality. A list of these mutations is provided in Supplementary material online, Table S1 .
Candidate predictors
The list of candidate predictors to be studied was based on the literature and was limited to those predictors that are typically available in a screening situation. We selected the following potential predictors: age; sex; history of CVD; age of first CVD event; current statin use; current use of other LLT; levels of LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides; body mass index (BMI); presence of diabetes; presence of hypertension; current smoking; amount of smoking; current alcohol use; and quantity of alcohol ingested per day. All candidate predictors were assessed at the time of screening for each subject. Cardiovascular disease was defined as a history of myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or ischaemic cerebrovascular accident.
Missing data
Missing values in the candidate predictor variables were imputed using the aregImpute command from the Hmisc package in R. 32 Missing values were imputed on the basis of all available clinical parameters in the dataset, including the outcome variable. Missing data were imputed five times; all analyses were then first performed separate for each imputed dataset and combined using the method described by Rubin.
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Statistical analyses
Differences in descriptive characteristics between FH patients and unaffected relatives were evaluated by logistic and linear regression analysis (for dichotomous and continuous variables, respectively) to account for family relations by means of the generalized estimating equation (GEE) method.
Model development
For model development, we used logistic regression analysis to examine the association between candidate predictors and the presence of an FH mutation. The strength of the relationship was expressed in regression coefficients with 95% confidence intervals (CI). First, to minimize the risk of excluding predictors that are deemed clinically relevant, but that do not reach statistically significance, we developed a preliminary model, with the following six preselected variables: age, sex, LDL-C, HDL-C, triglyceride level, and history of CVD. This will be the basic model for all subsequent models. Second, we explored which combination of the other candidate predictors (i.e. current statin use, current use of other LLT, presence of diabetes, presence of hypertension, current smoking, amount of smoking, current alcohol use, and amount of alcohol use) predicted the outcome best when added to the preliminary model. An extensive description of the evaluation of the predictors (regarding optimal form of coding, non-linearity, and interaction terms) and model building is provided in the supplementary material online.
All regression analyses were performed using the GEE method to account for potential correlated outcomes between patients within the same family. The exchangeable correlation structure was used for these models. P-values are two-sided, and significance level was set at ,0.01.
Model performance was assessed by both discrimination, expressed as the area under the receiver operating characteristic curve (AUC), and calibration, visualized in a calibration plot, and quantified by the slope of the calibration line. Furthermore, positive and negative predictive values (PPV and NPV, respectively) as well as sensitivity and specificity of two cut-off probabilities within the model are provided to illustrate model performance in clinical practice. Internal validation was evaluated by determining the AUC in 100 bootstrap samples.
Model validation
To externally validate our model, the predicted probabilities were calculated for each patient in the validation set using the regression coefficients and intercept from the original model as determined in the development cohort. In a calibration plot, the actual and predicted probabilities were compared across the range of predicted risks. Discrimination in the validation cohort was assessed with the AUC.
All analyses were carried out using the R statistical package version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria).
Sample size
To obtain unbiased estimates of the regression coefficients, it has previously been suggested to include at least 10 events per degree of freedom in the predictors in logistic regression analysis. 34 Furthermore, Vergouwe et al. showed that a minimum of 100 events and 100 non-events in a validation sample provide sufficient power to accurately determine performance of a model with six predictors. 35 We decided to limit the maximum number in the final model to 10 predictors to assure convenience in the use of the model. Therefore, the development and the validation cohort require a minimum of 200 FH patients and 200 non-FH patients.
Results
Description of the development cohort
From January 1994 until January 2014, a total of 64 171 individuals underwent DNA analysis for FH. Of these, we excluded a total of 65 (0.1%) homozygous FH patients. The remainder comprised our development cohort, of whom 26 167 (40.8%) were HeFH mutation carriers and 37 939 (59.2%) were unaffected relatives [36 804 (97.0%) non-carriers and 1135 carriers of non-deleterious mutations (3.0%)]. Demographic and clinical characteristics of subjects included in the development cohort, as well as the number of missing values per parameter, are shown in Table 1 . Compared with unaffected relatives, FH patients were younger, had on average lower values of BMI, drank less alcohol, smoked less often, had experienced more CVD, had lower prevalences of hypertension and diabetes, used statins and other LLT more often, and showed increased levels of total cholesterol and LDL-C and lower levels of HDL-C and triglycerides.
Description of the external validation cohort
A total of 3203 patients visited the Chicoutimi Hospital Lipid Clinic between January 1993 and January 2014 and were tested for the presence of an FH mutation. Of these, 1436 (44.8%) were heterozygous FH mutation carriers and 1767 (55.2%) were unaffected subjects.
Demographic and clinical characteristics of subjects included in the validation cohort, as well as the number of missing values per parameter, are shown in Table 2 . They were more often of male sex and older, had higher levels of BMI, and tended to use tobacco and alcohol more compared with persons in the development cohort. Furthermore, the prevalences of CVD, hypertension, diabetes, and statin use of other LLT were higher. Levels of total cholesterol, LDL-C, and triglycerides were higher in the external validation cohort, while levels of HDL-C were lower.
Prediction model
Our final model included age; sex; levels of LDL-C, HDL-C, and triglycerides; history and age of CVD; use of statins; smoking; alcohol; and presence of hypertension. The optimal transformation for age and LDL-C revealed to be the square root, and HDL-C and triglyceride levels predicted the outcome best when log-transformed. Five interaction terms were found to be significantly and independently associated with the presence of an FH mutation and were added to the model. These were 'age and LDL-C level', 'CVD and sex', 'CVD and alcohol use', 'CVD and statin use', and 'CVD and presence of hypertension'. All predictors (with appropriate transformations), interaction terms, and corresponding regression coefficients (with 95% CI) are provided in Table 3 . These coefficients were used to construct an interactive web-based calculator that can be used to calculate the probability of the presence of an FH mutation in individual subjects (http://vasculaironderzoekamc .nl/fh-calculator/). An extensive description of the results at the several steps in the model building procedure is provided in the supplementary material online. 
Model performance in development cohort
The AUC of the final model was 85.4% (95% CI: 85.0 -85.9) (Figure 1,  blue) . The calibration plot with the predicted probability plotted against the observed proportion of patients with an FH mutation is depicted in Figure 2 (left panel). The slope of the calibration line was 1.02 (optimal slope is 1.00).
To illustrate the performance of the model, we have summarized the PPV, NPV, sensitivity, and specificity at two different cut-off probabilities (0.30 and 0.70) in Table 4 . For example, 29 331 (45.8%) persons had a predicted probability of 0.30 or lower. Of these, 25 473 (86.8%) did not carry an FH mutation and 3857 were found to have an FH mutation (14.7% of all FH patients).
On internal validation, the AUC was slightly higher in 100 bootstrap samples than in the original development dataset, 85.5 (95% CI: 84.9-86.0).
External validation
The AUC of our model was 95.4% (95% CI: 94.7-96.1) (Figure 1, red) in the external validation cohort, which was substantially higher compared with the AUC of internal validation. The slope of the calibration line was 1.06 [ Figure 2 (right panel, red) ], which is considered moderate. Furthermore, our model underestimated the probability of an FH mutation in the external validation cohort. However, this was largely reduced upon recalibration, i.e. adjusting the intercept of our model for the diverging baseline risk for FH in the validation cohort [ Figure 2 (right panel, purple); see Supplementary material online for more extensive description].
Discussion Main findings and interpretation of results
We developed and externally validated a model to predict the presence of an FH mutation in persons suspected for having an FH mutation. The model was based on predictors that are readily available in every day clinical practice, i.e. age; sex; levels of LDL-C, HDL-C, and triglycerides; history and age of CVD; smoking status; use of alcohol; use of statins; and presence of hypertension. The performance of the model was considered to be good, based on an AUC of 85.4% (85.5% in 100 bootstrap samples) and a calibration slope of 1.02, and an AUC of 95.4% and calibration slope of 1.06 in a validation cohort. 
Genetic testing for familial hypercholesterolaemia
A prediction model typically performs less well in new patients. Therefore, the higher AUC found in the external validation cohort when compared with the development cohort was unexpected. This might be caused by differences in the procedure for selecting individuals for molecular testing between the development cohort and the validation cohort; the former comprises individuals identified by cascade screening and the latter comprises patients who visited an outpatient lipid clinic. The selection of participants in the cascade screening approach is relatively unbiased; all first-degree family members of index cases are tested for the presence of an FH mutation irrespective of their lipid and risk profile. In the validation cohort, however, patients were screened for mutations at the discretion of the treating physician, which is subject to referral bias. It might very well be that molecular screening is sometimes used 'to rule out' FH in individuals, not fully meeting the clinical criteria for FH. This might result in a more pronounced distinction between The model can be used by applying the following formula: probability of an FH mutation ¼ 1/(1 + exp ( CVD is defined as myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or ischaemic cerebrovascular accident. c Premature CVD is defined as a CVD event before the age of 55 (in men) or 60 (in women).
those who carry a mutation and those who do not, which will give rise to an increase in discrimination, and hence a higher AUC in the validation cohort.
The more pronounced distinction between mutation carriers and unaffected subjects in the validation cohort is also reflected in the calibration plot. In the four lowest deciles of predicted probability, the proportion of patients actually carrying a mutation does not exceed 0.10. At the other end of the spectrum, in the three upper deciles, the proportion of patients with a mutation is consistently .0.9. The calibration plot is therefore difficult to interpret. The calibration seems reasonable, with a slope of 1.06, although the figure also clearly indicates that our model overestimates the probability of an FH mutation in this validation cohort. The overestimation was largely reduced after recalibration for the diverging baseline risk for FH in the validation cohort.
Findings in relation to previous published diagnostic algorithms
The SB 15 and DLCN 17 criteria are the most commonly used diagnostic algorithms for FH, and these produce scores that lead to classification of either 'definite' or 'probable' FH. In patients classified as 'definitive FH', mutation detection rates ranged between 61 and 73% and 54 and 70%, respectively. 18 Using our model, however, 86.1% of all persons with a predicted probability of 0.7 or higher had an FH mutation. If our model is used to classify patients who are likely not to carry an FH mutation, 86.8% of all individuals with a predicted probability of 0.3 or lower according to our model did not carry an FH mutation. Damgaard et al. found that 85.7 and 94.1% of subjects designated as 'not having FH' according to the SB and DLCN criteria, respectively, did not carry an FH mutation. 18 These figures indicate that our model is well suited to select patients eligible for DNA analysis, while it performs equally well in ruling out FH in comparison with existing criteria. Of note, the DLCN criteria contain four categories of probability of having an FH mutation. The cut-off level of 0.3 of our model might therefore be too high and not similar to the category 'not having FH'. An independent study comparing the SB and DLCN criteria, as well as our current model, is warranted to fully address the differences in the performance.
Clinical applicability
The sets of clinical criteria that are currently widely applied for the diagnosis of FH primarily include a combination of high cholesterol, presence of tendon xanthomata, and/or arcus cornealis in the Genetic testing for familial hypercholesterolaemia patient; or first-or second-degree relative and a family history of premature CHD or high cholesterol. A number of these are likely to arise only in advanced stages of the clinical course of FH. Tendon xanthomas, for example, are clinical hallmarks almost never encountered in children with FH. 36 Moreover, LDL-C levels are an essential part of the clinical criteria, and using them in a categorical fashion, regardless of age, greatly ignores the fact that LDL-C levels do vary with age. 37 Consequently, children with FH rarely present with LDL-C levels that would classify them as 'definite FH', and the fact that fixed LDL-C cut-off levels are applied might result in falsely classifying young patients as 'not having FH'. To avoid these limitations, we did not include presence of tendon xanthomas or arcus cornealis in our model, and we analysed LDL-C level as a continuous predictor, while adjusting for age. We consider these modifications to be an improvement of the model, especially for young FH patients. This assumption is supported by the higher AUC in lower tertiles of age (see Supplementary material online, Table S6 ). For reasons of applicability and ease of use, we also did not include the presence of premature CVD or high cholesterol in family members as a potential predictor. It has been shown that information on these parameters is often either absent or inaccurate in medical records, 22 or hard to recall by patients. 23 This hampers the wide use of the currently available diagnostic criteria, where 'family history' does play an important role.
To facilitate the use of our prediction model in daily clinical practice, we intend to develop a smartphone application and an interactive web-based calculator that can be used to test the probability of the presence of an FH mutation in individual patients. Furthermore, we will provide test characteristics (PPV, NPV, sensitivity, and specificity) of our model when using different cut-off values. This can facilitate decision-making by physicians and patients at an individual patient level, because personal preferences can be taken into account. For example, when costs of DNA testing are high, and one wants to be absolutely sure of excluding the presence of an FH mutation to avoid testing, a lower cut-off level can be applied. In our population, 32% of all subjects had a predicted probability of 0.2 or lower, and the NPV of that cut-off level was 90%. By applying the cut-off level of 0.2 in our model, a physician who is consulted by 100 patients can thus refrain from DNA testing in 32 of them with 90% certainty that they will not have an FH mutation. The costs for the genotyping of a single gene were E82 249 in 2014 in the Netherlands. 38 Avoiding analysis of the three genes currently known to cause FH by using this cut-off level in our model would These figures might suggest that our model might lead to a costsaving effect, although this is only a theoretical calculation, and based on two separate cohorts. Analysis of all existing models in an independent study population will provide the final verdict on cost-effectiveness. Our model cannot be applied to all persons in the general population; a suspicion for FH has to be present (e.g. an increased LDL-C level in routine medical check-up). This is the consequence of the selection of the subjects in the development cohort. Most persons (93.0%) were tested for an FH mutation because they were firstdegree relative of a carrier of an FH mutation, without knowledge on lipid and risk profile. The clinical suspicion for an FH mutation was therefore low in these patients, and our model can be applied to individuals with similar characteristics.
Methodological considerations
There are some important methodological considerations when developing a prediction model: the selection of predictors, potential overfitting, and the number of events per predictor. These are discussed below.
Several approaches can be used to select predictors for the final model. 39 One approach is stepwise selection without taking previously known associations between candidate predictors and the outcome into account. A disadvantage is that variables might be excluded for being statistically insignificant in the multivariable model, while they would be significant if the model was built in another cohort. On the other hand, building a model using only predictors that were previously shown to be associated with the outcome, ignoring associations that appear in the data, can result in exclusion of yet unidentified but important predictors. To find balance between these two methods, we used a two-step approach to select the predictors in our model. First, we built a preliminary model that included all variables that we deemed to be important, in order to prevent their exclusion from the model when stepwise selection with a selection criterion was applied. On the basis of the clinical phenotype of FH, 8 we included LDL-C level and history of CVD. Since LDL-C levels differ between men and women, as well as with age, 26, 27, 36, 37 these two variables were added as well. Last, we included two other parameters of the lipid profile, HDL-C and triglycerides, to balance LDL-C levels. Second, the combination of eight potential predictors that fitted the data best was added to the model. We allowed a maximum of four predictors to be added to ensure that the final model did not contain too many predictors and would become unpractical to work with. As a selection criterion, we preferred an information criterion reflecting the fit of a variable to the data, instead of a P-value, since the latter only provides information on significance of the association between the predictor and the outcome, and not on the strength of the association. linearity with the outcome and thus using their predictive potential to full extent. Overfitting refers to the phenomenon that a model is developed using specific data, and as a result, the model will fit this data very well. 39 The apparent performance of the model in the development dataset is an overestimation of the performance in new patients. Prediction models that are developed using a dataset with small sample size are therefore more susceptible to overfitting. 40 The development cohort for our model was large (n ¼ 64 105), and consequently, we deem overfitting not to be an issue. The excellent performance in the external validation cohort supports this statement. Unreliable estimates of the regression coefficients of a model can occur when ,10 events per predictor are used. 34 To overcome this matter, we intended to include at least 200 FH patients and 200 unaffected persons in both the development and the validation cohort. Both cohorts were of sufficient sample size (26 167 FH patients vs. 37 939 unaffected subjects, and 1436 FH patients and 1767 unaffected subjects, respectively). One characteristic of the data of development cohort is the substantial number of missing values regarding BMI and lipid profiles. The latter is likely due to the fact that lipid parameters were measured by default only since 2004. Missing data might cause biased estimates of regression coefficients when persons in whom all data are available (complete cases) differ systematically from persons with missing values. 39 We used multiple imputation to prevent this, and as a sensitivity analysis, we constructed a model using complete cases from the development cohort only (see Supplementary material online). The variables that were included in this model differed slightly from the original model, as were the regression coefficients. Although this model performed slightly better in the validation cohort than in the original model, the regression coefficients of the latter are probably less biased.
Conclusion
We developed a new model to predict the presence of a deleterious FH mutation, based on an unprecedented number of genotypically defined FH patients and their unaffected family members. Our model performed very well in an independent validation cohort. We expect our model to perform equally well, or maybe even better, compared with current sets of selection criteria, when it comes to selecting patients eligible for DNA analysis for an FH mutation, as well as excluding the presence of an FH mutation. It might even be associated with a reduction in costs of DNA analysis. However, direct comparison of our model with current sets of selection criteria is warranted. Our algorithm is broadly applicable, and the intended publication as a smartphone application, as well as on a website, will facilitate the use in clinical practice.
